We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-3.56%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.78B
AUM Growth
+$176M
Cap. Flow
-$78M
Cap. Flow %
-2.8%
Top 10 Hldgs %
39.13%
Holding
109
New
17
Increased
24
Reduced
19
Closed
12

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$94.3M
2
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$60.3M
3
AERI
Aerie Pharmaceuticals
AERI
+$54.9M
4
XENT
Intersect ENT, Inc
XENT
+$29.7M
5
CHRS icon
Coherus Oncology
CHRS
+$29.1M

Top Sells

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$90.8M
2
CNC icon
Centene
CNC
+$19.7M
3
AXGN icon
Axogen
AXGN
+$18.7M
4
GKOS icon
Glaukos
GKOS
+$17.9M
5
ASND icon
Ascendis Pharma A/S
ASND
+$17M

Sector Composition

Rank Sector Weight
1 Healthcare 67.69%
2 Financials 0.96%
3 Consumer Discretionary 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
76
Spyre Therapeutics
SYRE
$8.7B
$3.42M 0.12%
20,002
– –
ADPT icon
77
Adaptive Biotechnologies
ADPT
$3.67B
$3.38M 0.12%
+70,000
New +$3.1M
PFNX
78
DELISTED
Pfenex Inc.
PFNX
$2.66M 0.1%
394,255
-523,932
-57% -$3.35M
CNST
79
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$2.25M 0.08%
183,600
-69,800
-28% -$777K
STIM icon
80
Neuronetics
STIM
$113M
$1.99M 0.07%
159,000
– –
ALPN
81
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.75M 0.06%
415,908
-59,542
-13% -$344K
HYPD
82
Hyperion DeFi Inc
HYPD
$41.5M
$1.29M 0.05%
3,750
– –
KIDS icon
83
OrthoPediatrics
KIDS
$494M
$1.25M 0.04%
32,000
– –
VYNE icon
84
VYNE Therapeutics
VYNE
$25.4M
$1.19M 0.04%
2,756
– –
TARA icon
85
Protara Therapeutics
TARA
$230M
$510K 0.02%
30,622
– –
NEOS
86
DELISTED
Neos Therapeutics, Inc
NEOS
$414K 0.01%
320,993
-1,478,148
-82% -$2.72M
ALLO icon
87
Allogene Therapeutics
ALLO
$618M
– –
-326,797
Closed -$9.45M
ASND icon
88
Ascendis Pharma A/S
ASND
$17.1B
– –
-144,194
Closed -$17M
EYPT icon
89
EyePoint Inc
EYPT
$1.12B
– –
-22,680
Closed -$406K
GKOS icon
90
Glaukos
GKOS
$9.21B
– –
-227,762
Closed -$17.9M
MGTX icon
91
MeiraGTx Holdings
MGTX
$1.15B
– –
-234,000
Closed -$4.03M
SVRA icon
92
Savara
SVRA
$1.13B
– –
-250,000
Closed -$1.84M
UHS icon
93
Universal Health Services
UHS
$9.15B
– –
-119,000
Closed -$15.9M
RVLP
94
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
– –
-846,048
Closed -$3.05M
SIOX
95
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-496,291
Closed -$5.28M
PTLA
96
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-2,617,543
Closed -$90.8M
MLNT
97
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
– –
-356,952
Closed -$1.27M
AAC
98
DELISTED
AAC Holdings
AAC
– –
-1,936,027
Closed -$3.56M
1 2 3
4

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q2 2019 Portfolio in Review

As of Q2 2019, Deerfield Management held 109 positions worth $2.78B, up 6.8% from $2.61B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Deerfield Management's Q2 2019 filing shows 17 new, 24 increased, 19 reduced and 12 closed positions. Its largest new stake was MALLINCKRODT PUBLIC LIMITED COMPANY: 4,178,219 shares worth $38.4M. The largest sale was Portola Pharmaceuticals, Inc., an estimated $90.8M.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 69% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Deerfield Management's largest Q2 2019 buy was MALLINCKRODT PUBLIC LIMITED COMPANY: 4,178,219 shares worth $38.4M.
  • Deerfield Management added most to Viatris in Q2 2019, an estimated $94.3M increase.
  • Deerfield Management's biggest Q2 2019 reduction was Centene, cutting an estimated $19.7M.
  • Deerfield Management fully exited Portola Pharmaceuticals, Inc. in Q2 2019, selling an estimated $90.8M.
  • Deerfield Management's ten largest holdings make up 39% of its $2.78B portfolio in Q2 2019.
  • Deerfield Management opened 17 new positions and closed 12 in Q2 2019.
  • Deerfield Management's portfolio value rose 6.8% quarter-over-quarter to $2.78B.

Based on Deerfield Management's 13F filing for Q2 2019, filed 14 Aug 2019.